DILH
BMRN icon

Dai-ichi Life Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dai-ichi Life Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-52,623
Closed -$4.87M – 70
2016
Q3 		$4.87M Buy
52,623
+35,166
+201% +$3.31M 0.15% 150
2016
Q2 		$1.36M Buy
17,457
+14,379
+467% +$1.22M 0.04% 359
2016
Q1 		$254K Sell
3,078
-6,748
-69% -$549K 0.01% 472
2015
Q4 		$1.03M Sell
9,826
-4,988
-34% -$521K 0.03% 394
2015
Q3 		$1.56M Buy
14,814
+430
+3% +$57.4K 0.05% 354
2015
Q2 		$1.97M Sell
14,384
-10,739
-43% -$1.33M 0.06% 307
2015
Q1 		$3.13M Buy
25,123
+21,035
+515% +$2.23M 0.09% 233
2014
Q4 		$370K Sell
4,088
-471
-10% -$39.2K 0.01% 467
2014
Q3 		$329K Hold
4,559
– – 0.01% 488
2014
Q2 		$284K Buy
4,559
+676
+17% +$40.8K 0.01% 527
2014
Q1 		$265K Sell
3,883
-415
-10% -$30.6K 0.01% 526
2013
Q4 		$302K Hold
4,298
– – 0.01% 507
2013
Q3 		$310K Buy
4,298
+1,110
+35% +$73.8K 0.01% 513
2013
Q2 		$178K Buy
+3,188
New +$199K 0.01% 592

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dai-ichi Life Holdings's BMRN Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 52,623 shares — an estimated $4.87M sold.

Dai-ichi Life Holdings first reported a position in BMRN in Q2 2013 and held it in 14 quarters. The position peaked at $4.87M in Q3 2016. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 52,623 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $4.87M.
  • Dai-ichi Life Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Dai-ichi Life Holdings's BioMarin Pharmaceuticals position peaked at $4.87M in Q3 2016.
  • 414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.